Evidence map›Paper›PMID 39210635›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Community recruitment of underrepresented populations to the AHEAD 3-45 preclinical AD trial using novel partnerships with nursing and community-based organizations: Lessons and outcomes.

Christian R Salazar, Melanie Tallakson, Maria G Corona, Edwin Duran, Eunji Russ, Dan Hoang, Romina A Romero, David L Sultzer, Joshua D Grill, Hye-Won Shin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Christian R SalazarUC Irvine Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.
Melanie TallaksonUC Irvine Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.
Maria G CoronaUC Irvine Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.
Edwin DuranUC Irvine Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.
Eunji RussUC Irvine Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.
Dan HoangUC Irvine Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.
Romina A RomeroUC Irvine Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.
David L SultzerUC Irvine Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.
Joshua D GrillUC Irvine Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.
Hye-Won ShinUC Irvine Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.

Funding

The Alzheimer's Clinical Trial Consortium - Down Syndrome Network (ACTC- DSN)U24AG057437 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Paul S. Aisen, RONALD C PETERSEN · 2018 to 2026
$198.4M
The Alzheimer's Disease Research Center at the University of California, IrvineP30AG066519 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Seyed Ahmad Sajjadi · 2020 to 2026
$27.9M
Improving Hispanic/Latino participation in preclinical Alzheimers disease TrialsK01AG076811 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Christian R Salazar · 2022 to 2026
$681k
ACTC AHEAD Alzheimer's Association Proposal: Diverse Recruitment Component SG-22-877415-AHEADAlzheimer's Association AARFD-20-682432NIA NIH HHS K01 AG076811NIA NIH HHS K01AG076811NIA NIH HHS P30 AG066519NIA NIH HHS P30AG066519NIA NIH HHS U24 AG057437NIA NIH HHS U24AG057437
6 · The paper itself

Abstract

introductionAlzheimer's disease (AD) disproportionately affects minoritized populations who remain underrepresented in AD trials.

methodsWe partnered with local nursing community-based organizations to implement a culturally tailored educational intervention and recruit Hispanic/Latino American, Filipino American, and Korean American adults aged 55 to 80 for the AHEAD study, a preclinical AD trial, at the University of California, Irvine.

resultsWe engaged 654 individuals across 21 events, leading to 71 prescreenings: 21.1% Filipino, 11.2% Hispanic/Latino, and 67.6% Korean adults. Ineligibility due to age and language barriers was common among Hispanic/Latino and Korean adults, respectively. Filipino adults often withdrew interest or were lost to follow-up. Ultimately, 25 participants enrolled: eight Filipino, two Hispanic/Latino, and 15 Korean adults. Tailored, culturally relevant content significantly contributed to the engagement success. DISCUSSION: This study demonstrates the value and impact of novel partnerships with health-related provider organizations that provide trusted care and access to underrepresented communities. HIGHLIGHTS: Six hundred and fifty four underrepresented individuals were reached, and 25 enrolled in the AHEAD 3-45 trial. Twenty-one community events were held via partnerships with nursing and community organizations. The study engaged 21% Filipino, 11% Hispanic/Latino, 68% Korean adults. Community-Based Participatory Research (CBPR) principles enhanced the recruitment process. Transparent communication and joint planning were key.

Indexed as

Alzheimer DiseasePatient SelectionAgedAged, 80 and overAsianCaliforniaFemaleHispanic or LatinoHumansMaleMiddle AgedPhilippinesRepublic of Koreacommunitydiversityinclusionminorityrecruitment

Identifiers

PMID39210635
PMCPMC11485091

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.